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Background: The recent evolution of limited local operative procedures for benign pancreatic lesions
shifted surgical treatment options to the application of local techniques, although major resections of
pancreatic head and left resection are still the standard.
Objectives: To evaluate the level of evidence of tumour enucleation (EN), pancreatic middle segment
resection (PMSR) and duodenum preserving total/subtotal pancreatic head resection (DPPHRt/s), we
focus based on present knowledge on indication to surgical treatment evaluating the questions, when
and how to operate.
Results: Tumour enucleation is recommended for all symptomatic neuro-endocrine tumours with size
up to 2e3 cm and non-adherence to pancreatic main-ducts. EN has been applied predominantly in
neuro-endocrine tumours and less frequently in cystic neoplasms. 20% of enucleation are performed as
minimal invasive laparascopic procedure. Surgery related severe post-operative complications with the
need of re-intervention are observed in about 11%, pancreatic ﬁstula in 33%. The major advantage of EN
are low procedure related early post-operative morbidity and a very low hospital mortality. PMSR is
applied in two thirds for symptomatic cystic neoplasm and in one third for neuro-endocrine tumours.
The high level of 33% pancreatic ﬁstula and severe post-operative complications of 18% is related to
management of proximal pancreatic stump. DPPHRt/s is used in 70% for symptomatic cystic neoplasms,
for lesions with risk for malignancy and in less than 10% for neuro-endocrine tumours. DPPHRt with
segment resection of peripapillary duodenum and intra-pancreatic common bile duct has been applied
in one third of patients and in two thirds by complete preservation of duodenum and common bile duct.
The level of evidence for EN and PMSR is low because of retrospective data evaluation and absence of RCT
results. For DPPHR, 7 prospective, controlled studies underline the advantages compared to partial
pancreaticoduodenectomy.
Conclusion: The application of tumour enucleation, pancreatic middle segment resection and duodenum
preserving subtotal or total pancreatic head resection are associated with low level surgery related early
post-operative complications and a very low hospital mortality. The major advantage of the limited
procedures is preservation of exo- and endocrine pancreatic functions.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The most frequent benign lesions of the pancreas are cystic
neoplasms and endocrine tumours [1,2]. Of cystic neoplasms
frequent are intra-ductal papillary mucinous neoplasms (IPMN),
mucinous cystic tumours (MCN) and serous cyst adenomas (SCA).
Insulinoma are the predominant neuro-endocrine tumour [3]. Up
to 50% of the reported benign lesions are clinically asymptomaticger).
by Elsevier Ltd. All rights reserveddetected by chance due frequent use of MD-CT, MRI, PET and EUS
investigations of the abdomen. Patients who complain episodes of
upper abdominal discomfort or have continuing clinical symptoms
in association with a cystic neoplastic lesion or neuro-endocrine
tumour are candidates for surgical treatment. In primary asymp-
tomatic patients with yet undetermined risk for developing
symptoms has been advocated to change to surgical treatment
based on the size of the lesion and tumour growth [4].
Neuro-endocrine lesions (PNETs) are 10% of all benign tumorous
lesions of the pancreas. Hormonal inactive and hormonal active
PNETs develop from cellular compartment of islet cell parenchyma.
Fig. 1. Main duct IPMN EM. 70 years, localised pancreatic head, max. diameter 4.8 cm,
mural nodule in cystic cavity; Histology: carcinoma in-situ.
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REVIEWwhich constitutes 2e10% of pancreatic tissue. In contrast to hor-
monal active PNETs, functional inactive endocrine tumours pro-
duce late in the course clinical signs which are mostly unspeciﬁc.
Besides of well-established radiological investigations and EUS, the
measurement of speciﬁc hormones in the peripheral blood, the
Somatostatin Receptor Scintigraphy and the PET are diagnostic
measures which establish in addition to speciﬁc hormone deter-
mination in blood in most patients the diagnosis, type and location
of the tumour. Multifocality of PNETs is well-known particularly in
case of hereditary syndromes like MEN-1.
After performing a selective literature review, we focus in the
following on the current knowledge about indication to surgical
treatment and the present experience applying limited surgical
techniques for benign cystic neoplasms and endocrine tumours.
Based on recently published data of a systemic review and meta-
analysis about use of tumour enucleation (EN), pancreatic middle
segment resection (PMSR) and duodenum preserving total and
subtotal pancreatic head resection (DPPHRt/s) for benign tumours,
data of early and late post-operative outcome are speciﬁcally dis-
cussed [5,6].
2. Natural history and treatment options of cystic neoplasm
and endocrine tumours
2.1. Cystic neoplasm
The natural clinical course of cystic neoplasm of the pancreas is
incompletely understood. IPMN lesions of main duct (MD-IPMN),
branch duct (BD-IPMN) and mixed type have variable clinical fea-
tures and different risks for a malignant transformation. MD-IPMN
are predominantly found inmen and localised in pancreatic head. A
transformation of benign adenoma to a cancerous process is
observed in up to 70%. In BD-IPMN cancer has been found in up to
35%. The ﬁve year risk of developing an invasive cancer for MD-
IPMN is calculated on basis of the present data being 63%, for BD-
IPMN 15% [7]. High-grade dysplasias are detected in MD-IPMN in
up to 62%; a carcinoma in situ, respectively an invasive carcinoma in
operative specimens are found in up to 45% (Table 1). In small BD-
IPMN, which are Sendai negative, a cancerous process in surgical
specimens found in up to 25% [19]. IPMN lesions show related to
histologic subtype’s expression of mucine patterns. The intestinal
sub-type contains MUC2 þ MUC5AC und CDX2, whereas the
pancreato-biliary subtype is characterised by MUC1 and MUC5AC
positivity but negativity for MUC2 and CDX2. The gastric-foveola
histological type of IPMN shows positivity of MUC5AC but nega-
tivity for MUC1, MUC2 and CDX2 [20e22].
MCN lesions are predominant in female patients located
frequently in body and tail of the pancreas. The differentiation of
MCN from IPMN is based onmulti-slice CTandMRT, but excluding a
malignant process by imaging tools only is difﬁcult [23]. MCN le-
sions are surrounded by a common capsula with a thick wall. His-
tologically, the diagnosis of MCN is established by presence of
ovarian type stroma. The clinical feature of MCN differs whether
they belong to the sub-group of mucinous cyst-adenoma or non-Table 1
Risk of malignancy in cystic neoplastic lesions of the pancreas.
Tumour size borderline High grade dysplasia
SCA >4 cm [25] 5.1%
IPMN-MD >3 cm [15] 57e62%
IPMN-BD >5 cm [15] 11% [17]
MCN >4 cm [15] >3 cm [18] 13.4% [11,12]
SPN >4 cm [14,26]invasive, proliferative MCN lesion with dysplasia or mucinous
cyst adeno-carcinoma. Mucinous cyst adenomas are 60% and non-
invasive, proliferative MCNs 30% of all MCNs [24].
Serous cyst adenomas are clinically not a rare entity; they
develop in different pathomorphological features: multiple micro-
cystic adenomas, single macro-cystic lesions with multiple crap-
like structures and macro-cystic tumours with one single cavity
[13]. SCA appear more frequently in the body and tail and are
detected most frequently in female patients. SCA are considered to
be rarely linked to malignancy. A malignant SCA and SCA in asso-
ciation with a remote ductal pancreatic cancer has been reported
from several centres. Generally a malignant potential of SCA is
considered to be low [2]. Solid pseudo-papillary neoplasms (SPN)
develop almost exclusively in female patients in middle ages below
50 years. An advanced cancer is found in resected solid pseudo-
papillary tumours in up to 22% [26,27].2.2. Neuro-endocrine tumours
Neuro-endocrine tumours of the pancreas are increasingly
detected; the average size is 2e3 cm. However, tumour size below
1 cm in operative specimens are not rare.
Up to 70% of all PNET’s are insulinoma which show most
frequently functional activity. Insulinoma are in 90% benign, inde-
pendently of the degree of clinical symptoms. Functional inactive
are 30e50% of all PNET’s, usually late detected in clinical course. All
gastroentero-pancreatic neuro-endocrine tumours are considered
to be potentially malignant [28]. The risk of malignancy of tumours
less than 2 cm in size, who show low degree of proliferation and
have tumour marker Ki67/MIB1 positivity index of <3% and are not
angio-invasive have a benign clinical course. PNET’s, which are
histologically well-differentiated, but associated by a Ki67/MIB1
positivity index between 3 and 20% are considered having a distinct
high risk for malignancy [29,30]. The vast majority of gastrinoma,
glucagonoma, vipoma and ACTH-PNET’s are malignant. 6e7% of all
PNET’s are low differentiated neuro-endocrine cancers [31].Carcinoma in-situ invasive carcinoma Risk of cancer
1.2% [13] 1.2%/5.1% [8,9]
43e45% [10] 63%/5 years [7]
15% [16] 25% [19] 14%/5 years [7]
36% [12] 17.3% [11,12] <15% [10]
19.2% [26]
Table 3
Tumours of the pancreas, surveillance of asymptomatic lesions.
Bd-IPMN: TM <3 cm
<1 cm
<2e3 cm
Observation
MRT, MSeCT yearlya
MRT/MRCP, MSeCT or EUS þ FNA yearlya
SCA TM <4 cm Observation
MSeCT yearlya
International Consensus Guidelines, Tanaka et al. Pancreatology 2012 [10].
a Change to surgical treatment in case of TM growth, mural nodule, cancer cell
positive, CEA increase >200 mg/dL in cystic ﬂuid.
H.G. Beger et al. / International Journal of Surgery 12 (2014) 606e614608
REVIEW3. When to operate benign cystic neoplasms and neuro-
endocrine tumours?
According to consensus guidelines of international expert
meetings published 2006 and 2012 symptomatic and asymptom-
atic patients with MD-IPMN should have operative treatment in
any case when they are surgically ﬁt (Fig. 1) [10,32]. For BD-IPMN,
surgery is recommended if tumour size is above 4e5 cm or the
cyst present signs of malignancy; but tumour size maybe a
misleading criteria for surveillance as recently has been shown [19]
(Table 2). Mural nodules, pancreatic main duct dilation above >5e
9 mm, wall thickening, rapid tumour growth are signs of a malig-
nant transformation and are indicators to change from surveillance
to surgery [10,32]. Solid mass in a cystic lesion is associated with
advanced IPMN cancer. Multifocality of IPMN lesions has become
increasingly important for decision making in symptomatic pa-
tients. The incidence of synchronus and metachronus multifocal
IPMNs are observed in up to 28% [33]. Branch duct-IPMNs have a
higher risk of multifocality as main-duct IPMN (see Table 3).
Surveillance of asymptomatic cystic neoplasms is recommended
for branch duct IPMN tumours of a size up to 3 cm. The surveillance
programme is based on use of MRT yearly for tumours below 2 cm
in max. diameter; above 2 cm additionally multi-slice CT are indi-
cated. In case of rapid tumour growth or development of mural
nodules an EUS with ﬁne needle aspiration is recommended to
exclude development of a cancerous process. The risk of malignant
transformation is high inMD-IPMN and lower in branch duct IPMN.
The borderline tumour size for MCN is considered to be 5 cm in
terms of decision making. Observation of asymptomatic serous cyst
adenomas is recommended up to tumour size of 4 cm by yearly
investigations. In serous pseudo-papillary neoplasia, carcinoma are
found in 19% of resected tumours. Surgical treatment has been
established for all patients suffering SPN because resection results
in cure of patients.3.1. Endocrine tumours
Candidates for surgical treatment are patients with endocrine
tumours who are clinically active lesions; asymptomatic PNETs
below the size of 1 cm are cared by a surveillance programme [30].
Pathomorphologically, endocrine tumours demonstrate occa-
sionally cystic changes, calciﬁcations and intra-lesional bleeding.
Most important criteria for decision making are clinical symptoms,
tumour size above 2 cm and risk of malignancy. Tumorous lesions
below 2 cm in diameter, who have a low proliferation index, are
mostly of benign nature; but endocrine neoplasms, showing cell-
grading G2 and a proliferation index Ki67/MIB1 >3e20% have a
distinctly increased risk of malignancy as it is for PNETs of a tumour
size above 2 cm, G1 cell grading and no signs of angioinvasion.
PNETs of tumour size below 2 cm, which have histological gradingsTable 2
Indication to surgical treatment in symptomatic and asymptomatic cystic neoplasia
of the pancreas.
Clinical symptomatic cystsa: Surgical extirpation for all lesions
Asymptomatic cystsa:
IPMN’s
Main duct Surgery for all lesions Observation,
TM > 4e5 cm surgeryBranch duct
MCN’s Surgery for all lesions
SCA Observation, cysts >4 cm surgery
SPsN Surgery for all lesions
Surgery is a cancer preventive treatment.
a International Consensus Guidelines, Tanaka et el. Pancreatology; 2006 [32] and
2012 [10].G2 and Ki67/MIB1 index of>20% have a high probability to develop
neuro-endocrine cancer [30,32]. Sporadic gastrinoma, glucago-
noma and vipoma of the pancreas are, irrespective of tumour size,
in >80% malignant lesions.
About 10% of sporadic hormone active insulinoma aremalignant
[34]. MEN1-associated insulinoma show infrequently signs of ma-
lignancy. Multifocality of PNETs is observed in MEN1 and VHL-
syndrome.
4. Options for surgical treatment of benign cystic neoplasms
and endocrine tumours
Most surgical institutions worldwide use for cystic lesions in the
pancreatic head a KauscheWhipple-type resection; and for a
benign cystic lesion in the body and tail of pancreas a spleen pre-
serving left pancreatic resection. But major surgical procedures are
burdened by additional sacriﬁce of normal functional pancreatic
and extra-pancreatic tissues and a considerable high level of severe
post-operative complications with a substantial risk of mortality. In
the late outcome after a Whipple-type resection, procedure related
late morbidity show an increase of exocrine insufﬁciency, a
dysfunction of the glucose metabolism, respectively new onset of
insuline dependent diabetes mellitus in about 20%. Episodes of
cholangitis in the long-term course after a Whipple-type resection
are underestimated. The recent evolution of limited surgical pro-
cedures established local resective techniques, but they are not yet
used as standard surgical treatment modalities for benign pancre-
atic tumours (Table 4). Tumour enucleation [34], pancreatic middle
segment resection [35] and duodenum preserving total or subtotal
pancreatic head resection [36] have the potential of a local tumour
extirpation associated with low procedure related post-operative
morbidity and preservation of the endocrine and exocrine
pancreatic functions compared to pre-operative status, respectively
to results after standard procedures.
5. Indications and limitation of local surgical procedures for
benign tumours of the pancreas
5.1. Tumour enucleation
Tumour enucleation has been used predominantly for neuro-
endocrine tumours of the pancreas. Of 709 patients, who hadTable 4
Options for surgical treatment of benign cystic and neuro-endocrine tumours of the
pancreas.
Limited surgical tumour extirpation
 Enucleation
 Pancreatic middle segment resection (central pancreatectomy)
 Duodenum-preserving total/subtotal pancreatic head resection
Presently standard procedures for benign TM’s
Pancreatic left resection  spleen preservation
Kausch-Whipple resection/Pylorus-preserving
(Total duodeno-pancreatectomy  spleen preservation)
Table 6
Indication and contra-indication to tumour enucleation in cystic neoplasia and
endocrine tumours of the pancreas.
Indication:
Cyst. TM Clinical symptomatic cysts <2e3 cm
Asymptomatic cysts <2e3 cm, age <50 years
TM no abutment to PMD
Absence of criteria of malignancy
PNETa Clinical symptomatic TMs < 2 cm
Asymptomatic TMs >1e2 cm
Hormone-active TMs <2e3 cm
Limitation of EN: PMD dilation
Histo-pathology: high grade dysplasia, carcinoma
(Multifocality)
TM close proximity to PMD
TM-size > 3 cm
TM suspected to be invasive cancer
PNET e pancreas neuro-endocrine tumour.
PMD e pancreatic main duct.
a Kunz PL et al. Consensus guidelines for the management and treatment of
neuro-endocrine tumours. Pancreas 2013; 42 : 557e577 [30] Ramage JK et al.
Guidelines for the management of gastroenteropancreatic neuro-endocrine tu-
mours. Gut 2005; 54 (IV) IV1-IV16 [117].
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was 2.4 cm [37e57]. 72% of the patients had enucleation of PNETs
and 22% for cystic neoplasms. Besides of the minimal tissue trauma
of pancreas, an additional beneﬁt of EN is application of laparo-
scopic techniques, which has been used in 20% of all patients. 55%
of enucleated endocrine tumours are located in pancreatic head,
45% in body and tail (Table 5).
The major risk of application of EN technique for benign tu-
mours lies in frequent development of pancreatic ﬁstula above 30%.
About half of the patients developed a ISGPF type B and C ﬁstula.
Pancreatic ﬁstula grade B and C contribute signiﬁcantly to post-
operative morbidity. Severe post-operative complications as
deﬁned by Clavian-Dindo score 3 [59], after EN developed in 11%.
The frequency of re-operation after enucleation of 4.7% and re-
hospitalisation of 11.8% may be related to the severity of type B
and C ﬁstula. The limitation of use of enucleation is size of lesion
and tumour proximity to pancreatic main duct. In case of tumour-
wall adherence to pancreatic main duct, injuring of duct increases
the risk of development of pancreatic ﬁstula. To avoid duct injuring
by enucleation, tumour size above 3 cm is a limiting criteria for
application of enucleation technique, particularly in association
with a pancreatic main duct dilation (Table 6).Table 7
Indication to duodenum preserving total/subtotal pancreatic head resection for
cystic neoplasms and endocrine tumours of the pancreatic head.
DPPHR total þ segment
duodenum þ CBD
TM abutment to duodenal wall
TM involving CBD
Ligation of SPGDA þ IPPDA Ischaemia5.2. Pancreatic middle segment resection
Pancreatic middle segment resection has been applied in 64%
for cystic neoplastic lesions and in 29% for neuro-endocrine tu-
mours according to a systematic review including 826 patients
reported between 1993 and 2010 [60e93] (see Table 7). The mean
tumour size was 2.9 cm. Pancreatic middle segment resection
produces in two resection surfaces of the pancreatic body. Resect-
ing a cystic neoplasm in a size of 5e6 cm, necessitates in most cases
additionally a tumour dissection close to walls of retro-pancreatic
vessels. Cystic tumours particularly main duct IPMN and MCN are
surrounded by a wall of inﬂammatory tissues, which frequently
extends to the splenic vein respectively, splenic artery. Tumour
encasement of vessels is associatedwith increased risk of blood loss
during and after operation. The frequency of severe post-operative
complications of 18% as well the high frequency of pancreatic ﬁstula
of 33% are related to management of the pancreatic stumps. The
crucial point of pancreatic middle segment resection is surgical
handling of the proximal pancreatic stump (Fig. 2). Whereas the left
pancreas is secured by a pancreatico-jejunostomosis or more
elegantly by pancreatico-gastrostomosis, the proximal pancreatic
stump is mostly handled by simple closure using mechanical de-
vices or by U-suturing of the tissue with isolated closure of the
pancreatic main duct. However, simple closure rather causes than
prevents local complications like ﬁstula or peri-pancreatic ﬂuid
collections. The frequency of post-operative haemorrhage has beenTable 5
Tumour size, location and early post-operative morbidity and mortality after
enucleation, pancreatic middle segment resection and duodenum preserving total/
subtotal pancreatic head resection for benign pancreatic tumours.
Cystic neoplasm PNETd Post-operative morbidity
Severe
complications
POPF Hospital
mortality
ENa 21.7% 72.0% 10.8% 33.1% 1.13%
PMSRb 64.0% 28.5% 17.7% 32.9% 0.81%
DPPHRt/sc 71.1% 7.9% 11.5% 19.9% 0.49%
a Tumour enucleation [38e58].
b Pancreatic middle segment resection [60e93].
c Duodenum preserving total/subtotal pancreatic head resection [51,97e116].
d Pancreatic neuro-endocrine tumours.observed in 7% and the re-hospitalisation in 14%. The increased risk
of severe type pancreatic ﬁstula derived from the proximal
pancreatic stump and frequency of haemorrhage contributes to the
high level of re-operation and re-admission after pancreatic middle
segment resection. Hospital mortality was with 0.8% very low (see
Fig. 3).
Applying pancreatic middle segment resection for large
tumorous lesions of the body of the pancreas necessitating a
resection of a pancreatic segment of more than 5e6 cm increases
the risk for metabolic dys-functions. After extended middle
segment resection of a large pancreatic segment, endocrine insuf-
ﬁciency in the long-term outcome is observed in up to 12% and
exocrine insufﬁciency in about 20% compared to pre-operative
levels [94]. For extended cystic neoplasms in the pancreas body a
spleen preserving hemipancreatectomy may be an alternative
procedure. However, the metabolic exo- and endocrine functions
after pancreatic left resection are clinically relevant decreased,
whereas the frequency of local complications found lower
compared to pancreatic middle segment resection.of peripapillary duodenum
Cystic neoplasm þ carcinoma in-situ
hi-PNEC > 2 cm
DPPHR total preservation
of duodenum and CBD:
TM extending to neck of pancreas
PNET functional active >2 cm
TM not including Duodenum þ CBD
DPPHR subtotal TM location in processus uncinatus
(uncinetectomy)
TM location in neck of pancreas
CBD not involved
Insulinoma >2 cm located in processus uncinatus
Limitation of DPPHRt Cystic neoplasm and advanced cancer
Islet carcinoma TM > 2 cm
DPPHRt e total pancreatic head resection.
DPPHRs e subtotal pancreatic head resection.
SPGDA e superior posterior gastro-duodenal artery.
IPPDA e inferior posterior pancreato-duodenal artery.
hi-PNEC e hormone inactive pancreatic neuro-endocrine carcinoma.
Fig. 2. Middle segment resection of the pancreatic body with two anastomoses. Duct-
to-duct anastomosis.
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For benign tumours of the pancreatic head a total and subtotal
head resection has been introduced in clinical practice between
1985 [95] and 1994 [96]. Location of the tumour within pancreatic
head and size of lesion determine the use of a subtotal or total head
resection. The surgical experience using duodenum preserving to-
tal pancreatic head resection is up to now limited [97e107]. Ad-
vantages are underlined by 7 prospective and controlled clinical
trials, comparing duodenum preserving total pancreatic head
resection with Whipple-type pancreatico-duodenectomy. Out of
405 patients reported between 1995 and 2003, one third had a total
pancreatic head resection including peripapillary segment of duo-
denum and intra-pancreatic common bile duct. One third of pa-
tients experienced total head extirpation, but preservation of
duodenum and common bile duct (Fig. 4a,b), one third had a sub-
total resection conserving pancreatic tissue between intra-
pancreatic common bile duct and wall of duodenum as well tis-
sue of the uncinate process (Fig. 5a,b). Surgical techniques of total
head resection, with dissection of pancreatic tissue from peri-
papillary duodenum and preserving the posterior and anterior
pancreatico-duodenal arcades arewell established. Total pancreaticFig. 3. Islet cell carcinoma, 3 cm in max. diameter; operative specimen after total
pancreatic head resection with segment resection of the duodenum and intra-
pancreatic common bile duct.head resection with segment resection of the peripapillary duo-
denum requires four anastomoses: end-to-end between proximal
and distal duodenum; end-to-side of common bile duct and post-
pyloric duodenum and end-to-side between preserved pancreatic
head or neck and the excluded jejunal loop and a Roux-en-Y
anastomosis. The low frequency of re-operation of 1.8%, hospital
mortality of 0.5% as well re-hospitalisation of 3.3% and 12.5% of
severe early post-operative complications underlines the well
standardised techniques of pancreatic head resection. Pancreatic
ﬁstula developed in 20% of patients, of them 47% grade B and C
ﬁstulas. A major advantage of duodenum preserving total and
subtotal pancreatic head resection is preservation of exo- and
endocrine functions compared to pre-operative level. In 7 pro-
spective controlled trials comparing a duodenum preserving total
head resection with a Whipple-type partial pancreatico-
duodenectomy, the metabolic functions after DPPHRt were signif-
icant better preserved. An additional advantage of this technique is
tailoring of head resection conserving neck of pancreas or uncinate
process or parts of dorsal pancreatic head segment. DPPHRt with
segment resection of peripapillary duodenum and common bile
duct has been additionally applied in cystic neoplastic lesions with
a carcinoma in-situ and T1 low risk cancer of the papilla, pre-
papillary common bile duct and peripapillary duodenal cancer.
However, the indication for local, non-invasive cancers are to be
proven by prospective controlled trials.
6. Comment
Local surgical procedures for benign tumours of the pancreas
are evolving operative techniques but presently not surgical stan-
dard. The evidence of tumour enucleation and pancreatic middle
segment resection is low, because exclusively based on retrospec-
tive clinical trials without control groups. Two prospective
controlled trials out of more than 30 retrospective studies have
been published comparing PMSRwith spleen preserving pancreatic
left resection in patients suffering chronic pancreatitis but the au-
thors did not include neoplastic tumours. PMSR exhibited advan-
tages in regard to preservation of metabolic functions, but showed a
higher level of surgery related early post-operative complications.
Duodenum preserving total and subtotal pancreatic head resection
is supported by 7 prospective controlled trials comparing early and
late results after Whipple resection applied mostly for benign
pancreatic head tumours. The controlled trials for DPPHRt/sFig. 4. OP situs after total pancreatic head resection with segment resection of peri-
papillary duodenum and intra-pancreatic common bile duct.
Fig. 5. a) Serous cyst adenoma of the uncinate process, 5 cm max. diameter, surgical
procedure: sub-total pancreatic head resection, resection of processus uncinatus. b)
Resection of cystic neoplasia of uncinate process. Subtotal pancreatic head resection,
respective resection of uncinate process with conservation of CBD and periampullary
duodenum.
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surgery-related complications, a very low hospital mortality <1%
and full conservation of exo- and endocrine pancreatic functions
early post-operatively and in late outcome of patients. Additional
advantages of the local surgical procedures are application of
laparoscopic or robotic techniques which are increasingly used for
tumour enucleation. Tailoring extension of tissue resection yields
limitation of sacriﬁce of pancreatic and extrapancreatic tissue.
Applying subtotal pancreas head resection by tumour location in
the processus uncinatus performing an uncinatectomy or in the
dorsal part or neck of pancreas contributes to main goal of avoiding
unnecessary sacriﬁce of pancreatic tissue. Tumour enucleation and
pancreatic middle segment resection are burdened by a higher rate
of pancreatic ﬁstula above 30%, of them ISGPF B and C of 50%. The
development of severe pancreatic ﬁstula and the increased level of
post-operative haemorrhage and frequency of re-hospitalisation
after EN and PMSR are considered as limitation of use of these
local resective techniques. In terms of the younger age of patients
suffering cystic neoplasms of SCA and SPN and PNETs, limited
surgical procedures are most beneﬁcial because of the very low
hospital mortality and full preservation of exo- and endocrine
functions of pancreas. In case of advanced cancer developed from
cystic neoplasms or invasive endocrine cancers, a standard majoroncologic resectionwith lymph node sampling and tissue resection
to achieve an R0 status is recommended (Table 4).
7. Summary
For benign cystic neoplasms and endocrine tumours the appli-
cation of tumour enucleation, pancreatic middle segment resection
and duodenum preserving subtotal and total pancreatic head
resection offer advantages of a limited pancreatic and extra-
pancreatic tissue trauma compared to major oncological resection
currently used as standard treatment. Tumour enucleation and
pancreatic middle segment resection are burdened with a distinct
risk of developing pancreatic ﬁstula ISGPF grade B and C, but have
advantage of a very low hospital mortality. The clinical evidence of
tumour enucleation and pancreatic middle segment resection is
low since the present knowledge is based only on retrospective
uncontrolled studies. Duodenum preserving subtotal and total
pancreatic head resection showed in comparison to aWhipple type
head resection signiﬁcant advantages in regard to maintenance of
the exo- and endocrine pancreatic functions in the short- and long-
term outcome. Prospective controlled trials are needed for evalu-
ation of the proposed advantages of limited surgical procedures.
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